Anzeige
Mehr »
Login
Mittwoch, 25.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Während die Wall Street über Krypto-ETFs debattiert, liefert dieses Unternehmen 1.000?% RENDITE!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
441 Leser
Artikel bewerten:
(2)

The Galien Foundation's Prix Galien UK Forum Returns to London in May 2024

Finanznachrichten News
  • Forum will be held on May 30 at the Science Museum, London
  • Chaired by Professor Sir Munir Pirmohamed, Forum to consist of four panel sessions highlighting solutions to pressing issues facing private and public-sector innovators in the healthcare space
  • Keynote presentation by Dr Miles Congreve, Chief Scientific Officer, Isomorphic Labs, and closing remarks from Dr Hilary Marston, Chief Medical Officer, Food and Drug Administration
  • Awards Ceremony to be hosted following Forum at the Natural History Museum, London

LONDON, May 2, 2024 /PRNewswire/ -- The Galien Foundation will celebrate the third annual Prix Galien UK Forum at the Science Museum in London, on May 30, 2024, from 9:30 AM - 5:00 PM. The Prix Galien UK Forum brings together industry scientists, researchers, and organisations at the forefront of scientific advancement to exchange and offer perspectives on the future of global health. Together with the evening Prix Galien Awards Ceremony recognising the best in UK medicine, the events reflect the worldwide mission of The Galien Foundation to improve the human condition through breakthrough innovations that progress the understanding in diagnosing, treating, and curing disease.

The Galien Foundation

"The Prix Galien UK Forum is an exemplary platform for scientific discussion and dynamic peer-led conversations on the most prevalent topics and challenges we face as professionals in the life sciences arena," commented Professor Sir Munir Pirmohamed, David Weatherall Chair of Medicine at the University of Liverpool and the NHS Chair of Pharmacogenetics, Chair of the Prix Galien UK Committee. "The Forum is an unmissable opportunity to delve into the leading minds working across a myriad of health-related research and product development areas."

This year's lineup will feature the following panels:

9:40 AM - 10:40 AM
PANEL 1: No decision for me without me: Putting patients at the heart of drug development
CHAIR
Dr Mel Walker, Life Sciences Strategic Advisor and Managing Director, BioPharma Futures

PANELISTS
Robyn Bent, Director of CDER's Patient-Focused Drug Development (PFDD) Program, FDA
Dr Sarah Gheuens, Chief Medical Officer, Head of R&D, Agios Pharmaceuticals
Dr Maria Mavris, Patient Liaison at European Medicines Agency
Elizabeth Vroom, Co-founder and chair of the World Duchenne Organization

11:00 AM - 12:00 PM
PANEL 2: Introducing New Technologies: Optimising pathways to improve population health
CHAIR
Dame June Raine, Chief Executive, Medicines and Healthcare products Regulatory Agency

PANELISTS
Pr Gary Ford, Chief Executive Officer, Health Innovation Oxford and Thames Valley
Hilary Hutton-Squire, Vice President, Head of Global Value and Access, Gilead Sciences
Sir Harpal Kumar, President, BioPharma Business & Europe, GRAIL, LLC
Dr Hakim Yadi, CEO, Closed Loop Medicine

12:45 PM - 1:30 PM
KEYNOTE ADDRESS: Can we use artificial intelligence to design new drugs?
Dr Miles Congreve, Chief Scientific Officer, Isomorphic Labs

1:30 - 2:30 PM
PANEL 3: Innovation in R&D: The birth of breakthroughs
CHAIR
Lord Prior of Brampton, Deputy Chairman UK and Global Senior Advisor at Lazard, Chairman of Protas; Chairman of the Cambridge Life Sciences Council and Chairman of Tympa Health

PANELISTS
Tamsin Berry, Co-founder and partner of Population Health Partners
Dr Joep Muijrers, General Partner, Gilde Healthcare
Dr Matthias Müllenbeck, SVP, Head Global Business Development & Alliance Management
Dr Jane Osbourn, CSO at Alchemab Therapeutics Ltd

2:45 - 3:55 PM
PANEL 4: Data Driven Medicine: The NHS as a strategic partner in life science
CHAIR
Dr Vin Diwakar, National Director for Transformation (interim), NHS England

PANELISTS
Dr Michelle Longmire, CEO & Co-Founder, Medable
Pr Andrew Morris, Director, Health Data Research UK & Professor of Medicine and Vice Principal Data Science, University of Edinburgh
Dr Adrian Rabe, Head of RWE Centre of Excellence, Boehringer Ingelheim Ltd.
Richard Stephens, Patient partner; Chair of use MY data, UK Cancer Research Advocates Forum
Ming Tang, Chief Data and Analytics Officer, NHS England

3:55 - 4:40 PM
CLOSING SPEECH
Dr Hilary Marston, Chief Medical Officer, Food and Drug Administration

Bruno Cohen, Chairman of the Galien Foundation, commented, "It is wonderful to welcome both returning and new industry thought leaders to the Prix Galien UK Forum stage. As the Forum enters its third year, the quality and breadth of our panel discussions continue to pave the way for a stronger, healthier, and sustainable future for global healthcare."

Following the Prix Galien UK Forum, the Prix Galien UK Awards Ceremony will take place at the Natural History Museum, London, from 7:30 PM - 10:30 PM. Under the leadership of Professor Sir Munir Pirmohamed, the Prix Galien UK Awards Committee will select the latest cohort of leading innovators and products in the life sciences industries to be awarded for their profound achievements.

To learn more about the 2024 Prix Galien Forum and Awards Ceremony, please visit: https://prixgalien.co.uk/.

To purchase a ticket to the events, please visit: https://join.galienfoundation.org/

About the Galien Foundation
The Galien Foundation fosters, recognises and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatments and technologies that will impact the state of medical practice and save lives.

The Foundation oversees and directs activities in the UK for the Prix Galien, an international awards programme dedicated to progress through innovative medicines development, with chapters in 14 countries, Africa and an inaugural chapter established in India in 2024. The Prix Galien was created in 1970 by Roland Mehl in honour of Galien, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

For more information, visit www.galienfoundation.org.

Follow the Foundation on social media:
https://www.facebook.com/GalienFoundation/
https://twitter.com/GalienFdn
https://www.linkedin.com/company/the-galien-foundation/

Media Contact (UK):
Julian Tyndale-Biscoe
Finn Partners
Julian.Tyndale-biscoe@finnpartners.com
+44 20 3217 7060

Media Contact (Global):
Kara Bradley
Finn Partners
Kara.Bradley@finnpartners.com
+1 646-213-7243

Logo - https://mma.prnewswire.com/media/564722/The_Galien_Foundation_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/the-galien-foundations-prix-galien-uk-forum-returns-to-london-in-may-2024-302133869.html

© 2024 PR Newswire
6 Richtige für 2025
Das Börsenjahr 2025 klopft schon an die Tür – und wie immer geht es um die Frage: Welche Aktien werden die großen Gewinner sein? Die Auswahl an Möglichkeiten ist riesig, doch nur ein paar echte Volltreffer stechen heraus.

Ob stabiler Dividenden-Lieferant, Tech-Pionier oder spekulative Wette im Krypto-Bereich – wir haben die Märkte für Sie ausgiebig durchforstet und präsentieren Ihnen 6 Unternehmen, die große Chancen auf außergewöhnliche Kurssteigerungen besitzen. Hier sind, speziell für Sie, Ihre „6 Richtigen“ für 2025.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche Unternehmen das Potenzial besitzen, im kommenden Jahr richtig durchzustarten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.